Former CEO Anne Wojcicki's nonprofit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe ...

Regeneron wins bid to buy 23andMe out of bankruptcy. Ned Pagliarulo . Mon, May 19, 2025, 4:00 AM 3 min read. In This Article: REGN . This story was originally published on BioPharma Dive.

Previous reports (including ours) said that a company named Regeneron was supposed to be the buyer, but that deal ended up falling through. Before the buyer had been selected in 23andMe’s bankruptcy ...

Regeneron Pharmaceuticals, a biotechnology company with a long history of large-scale genetics research, plans to buy DNA testing firm 23andMe out of bankruptcy, announcing Monday it was named the ...

-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies. Regeneron, a biotech company, ...

Co-founder Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron's offer for the DNA-testing company in a bankruptcy auction.

Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a bankruptcy auction. Regeneron said it will acquire 23andMe's genomics service ...

Regeneron's planned acquisition of 23andMe raises significant privacy concerns as experts warn about the lack of comprehensive federal regulations governing the transfer of genetic information.

Regeneron said in its statement that as the named buyer in the bankruptcy auction, it “intends to ensure compliance” with 23andMe’s privacy policies and laws regarding customer data.